205 related articles for article (PubMed ID: 8678492)
1. [Treatment for hormone-refractory or relapsing prostatic cancer].
Hirao Y; Ozono S; Okajima E
Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492
[TBL] [Abstract][Full Text] [Related]
2. [Chemotherapy of prostatic cancer].
Hirao Y; Kubota K; Yoshie T; Tabata S; Samma S; Ozono S; Okajima E; Sasaki K; Yoshikawa M; Tsumatani K
Hinyokika Kiyo; 1991 Aug; 37(8):817-24. PubMed ID: 1720273
[TBL] [Abstract][Full Text] [Related]
3. [Clinical evaluation of chemotherapy in urologic cancer].
Miki T; Kuroda M; Kotake T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1349-57. PubMed ID: 2471457
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
6. [Response to chemotherapy in endocrine therapy-relapsed and -resistant prostate cancer].
Akimoto S; Akakura K; Masai M; Shimazaki J
Hinyokika Kiyo; 1991 Jan; 37(1):31-7. PubMed ID: 1707216
[TBL] [Abstract][Full Text] [Related]
7. [Cyclophosphamide, adriamycin and cisplatinum combination chemotherapy for advanced urothelial and prostatic carcinoma].
Tsukamoto T; Tanoguchi H; Nakazono M; Murai M; Tachibana M; Deguchi N; Baba S; Hata M; Jitsukawa S; Tazaki H
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3259-64. PubMed ID: 3688891
[TBL] [Abstract][Full Text] [Related]
8. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
9. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
10. [Preliminary report on the effect of etoposide or etoposide and CDDP on recurrent prostate cancer].
Suzuki K; Nakamura T; Kato N; Kurita M; Nakazawa Y; Suzuki T; Imai K; Yamanaka H
Hinyokika Kiyo; 1991 Nov; 37(11):1499-503. PubMed ID: 1767772
[TBL] [Abstract][Full Text] [Related]
11. [The role of etoposide therapy in urogenital cancer].
Kawai K; Akaza H
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1929-35. PubMed ID: 8978800
[TBL] [Abstract][Full Text] [Related]
12. [Induction therapy with CDDP and ADM for stage D prostatic cancer and its clinical response].
Yushita Y; Sakai H; Nomata K; Suzu H; Minami Y; Ogawa S; Yamashita S; Kanetake H; Saito Y
Hinyokika Kiyo; 1990 Dec; 36(12):1415-21. PubMed ID: 2075879
[TBL] [Abstract][Full Text] [Related]
13. [New combination chemotherapy in refractory rhabdomyosarcoma of the prostate: a case report and review of the literature].
Takeuchi T; Komeda H; Oguchi K; Ishihara S; Iwata H; Kanematsu M; Kuriyama M; Ban Y; Tanaka T
Hinyokika Kiyo; 1987 Nov; 33(11):1899-905. PubMed ID: 2451411
[TBL] [Abstract][Full Text] [Related]
14. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
15. [Intra-arterial chemotherapy of relapsed and hormone-resistant prostate cancer using reservoir system].
Ueno K; Shinoda I; Takahashi Y; Kawamoto S; Yamamoto N; Kuriyama M; Kawada Y; Nagatani Y; Takeuchi T; Sakai S
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1783-7. PubMed ID: 2389965
[TBL] [Abstract][Full Text] [Related]
16. Management of hormone refractory prostate cancer: current standards and future prospects.
Oh WK; Kantoff PW
J Urol; 1998 Oct; 160(4):1220-9. PubMed ID: 9751323
[TBL] [Abstract][Full Text] [Related]
17. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
18. [Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostatic cancer].
Takeuchi S; Fukui I; Higashi Y; Andoh M; Kihara K; Kitahara S; Horiuchi S; Oshima H
Hinyokika Kiyo; 1989 Sep; 35(9):1513-7. PubMed ID: 2816618
[TBL] [Abstract][Full Text] [Related]
19. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
20. [Combination chemotherapy with ifosfamide (or cyclophosphamide), adriamycin, cis-platinum and peplomycin (IAPP) for hormonally resistant metastatic prostatic cancer].
Maeda O; Saiki S; Kinouchi T; Kuroda M; Miki T; Usami M; Kotake T
Hinyokika Kiyo; 1991 Dec; 37(12):1657-62. PubMed ID: 1723841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
